PRIMARY AL AMYLOIDOSIS: NEW INSIGHTS INTO ITS PATHOGENESIS, DIAGNOSIS, AND TREATMENT
- Authors: Rameev V.1, Kozlovskaya L.1, Gudkova K.1, Kogarko I.2, Kogarko B.1,2
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- N.N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
- Issue: Vol 24, No 1 (2013)
- Pages: 58-60
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115600
- ID: 115600
Cite item
Open Access
Access granted
Abstract
The rate of production of the amyloid precursor protein - free immunoglobulin light chains (FLC) - is an important factor for estimating disease prognosis and therapeutic effectiveness. A 3-fold FLC reduction as compared to the normal values has increased the chances of a good prognosis by about 6 times.
Keywords
Full Text
About the authors
V. Rameev
I.M. Sechenov First Moscow State Medical University
Email: vvrameev@mtu-net.ru
L. Kozlovskaya
I.M. Sechenov First Moscow State Medical University
K. Gudkova
I.M. Sechenov First Moscow State Medical University
I. Kogarko
N.N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
B. Kogarko
I.M. Sechenov First Moscow State Medical University; N.N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
References
- Glenner G., Terry W., Harada M. et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analysis // Science.-1971; 172: 1150-1.
- Bradwell A. Serum free light chain analysis, 4th ed. The Binding Site Ltd., Birmingham, UK. 2006.
- Kyle R., Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases // Seminars in Hematology. - 1995; 32: 45-59.
- Skinner M., Anderson J., Simms R., et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicines versus colchicines only // Am. J. Med. - 1996; 100: 290-8.
- Comenzo R., Vosburgh E., Simms R. et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients // Blood. - 1996; 88: 2801-6.
- Jaccard A., Moreau P., Leblond V. et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis // N. Engl. J. Med. - 2007; 357 (11): 1083-93.
- Reece D., Hegenbart U., Sanchorawala V. et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study // Blood. - 2011; 118: 865-73.
- Gertz M., Buadi F., Hayman S. Treatment of Immunoglobulin Light Chain (Primary or AL) // Amyloidosis Oncol. - 2001; 25 (7): 15.
Supplementary files
